A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

  • Markman, Ben (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA Reference Number: HREC/16/QRBW/71
SSA Reference Number: SSA/16/MonH/144
Monash Health HREC Ref: 16204X
Effective start/end date12/12/188/02/21